The Scientist magazine named Sigma-Aldrich CRISPR Epigenetic Activator "20,150 innovation products".

The Scientist magazine, "top ten innovative product" award dCas9-p300 system is highly positive impetus to the cause of human health, this product has spawned new drug screening, gene therapy, and disease surveillance platform.

DCas9-p300 uses a single gRNA activation levels of endogenous gene expression, simplifying the application of genetic modification tool, based on genome-wide screening of gene activation and opens up new avenues of research.

Sigma-Aldrich CRISPR Epigenetic Activator, through specific histone acetylation, activation of target genes, and achieved under the premise of not changing the DNA sequence of the genome modification.Sigma-Aldrich Nominum Qingzhou Ji led research teams to apply gene editing CRISPR technology expands to epigenetic level editor.Ji compared epigenetic activators in order to enter the room key: "we want to know what is happening inside the room, but we don't want to disrupt the entire layout of the room, we just opened the door and walked in. ”"Saw the development of the dCas9-p300 system in the process of innovation to get recognition in the industry, we feel gratified.Life sciences endogenous genes activated in the past has been the lack of effective tools, "Merck KGaA life science business unit molecular biology Supriya Shivakumar, Director of product management, said," now, we finally have a set of applicable target epigenetic regulation and transcriptional regulation of powerful programming tool. ”